PRELUDE THERAPEUTICS INC Operating Lease, Payments
PRELUDE THERAPEUTICS INC (PRLD) reported Operating Lease, Payments of $1.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC operating lease, payments for the quarter ending 2026-06-30 was $734.00K, a 18.39% increase year-over-year.
- PRELUDE THERAPEUTICS INC operating lease, payments for the quarter ending 2026-03-31 was $734.00K, a 18.39% increase year-over-year.
- PRELUDE THERAPEUTICS INC operating lease, payments for the quarter ending 2025-12-31 was $734.00K, a 37.97% increase year-over-year.
- PRELUDE THERAPEUTICS INC operating lease, payments for the quarter ending 2025-09-30 was $734.00K, a 25.68% increase year-over-year.
- PRELUDE THERAPEUTICS INC operating lease, payments for fiscal 2025 was $2.71M, a 71.07% increase from fiscal 2024.
- PRELUDE THERAPEUTICS INC operating lease, payments for fiscal 2024 was $1.58M, a 17.89% decline from fiscal 2023.
- PRELUDE THERAPEUTICS INC operating lease, payments for fiscal 2023 was $1.93M, a 7.11% increase from fiscal 2022.
- PRELUDE THERAPEUTICS INC operating lease, payments for fiscal 2022 was $1.80M.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month | Operating Lease, Payments 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $734.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.47M 10-Q · filed 2026-08-11 | $2.20M derived: sum of 3 quarters · filed 2026-08-11 | $2.94M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $734.00K 10-Q · filed 2026-05-12 | $1.47M derived: sum of 2 quarters · filed 2026-05-12 | $2.20M derived: sum of 3 quarters · filed 2026-05-12 | $2.82M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | $734.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $1.47M derived: sum of 2 quarters · filed 2026-03-10 | $2.09M derived: sum of 3 quarters · filed 2026-08-11 | $2.71M 10-K · filed 2026-03-10 | |
| 2025-09-30 | $734.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.35M derived: sum of 2 quarters · filed 2026-08-11 | $1.97M 10-Q · filed 2025-11-12 | $2.51M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $620.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.24M 10-Q · filed 2026-08-11 | $1.77M derived: sum of 3 quarters · filed 2026-08-11 | $2.36M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $620.00K 10-Q · filed 2026-05-12 | $1.15M derived: sum of 2 quarters · filed 2026-05-12 | $1.74M derived: sum of 3 quarters · filed 2026-05-12 | $2.20M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $532.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $1.12M derived: sum of 2 quarters · filed 2026-03-10 | $1.58M derived: sum of 3 quarters · filed 2026-03-10 | $1.58M 10-K · filed 2026-03-10 | |
| 2024-09-30 | $584.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.05M derived: sum of 2 quarters · filed 2025-11-12 | $1.05M 10-Q · filed 2025-11-12 | $1.53M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $467.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $467.00K 10-Q · filed 2025-08-14 | $949.00K derived: sum of 3 quarters · filed 2025-08-14 | $1.43M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 | $482.00K derived: sum of 2 quarters · filed 2025-03-10 | $964.00K derived: sum of 3 quarters · filed 2025-03-10 | $1.43M derived: sum of 4 quarters · filed 2025-03-10 | |
| 2023-12-31 | $482.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $964.00K derived: sum of 2 quarters · filed 2025-03-10 | $1.43M derived: sum of 3 quarters · filed 2025-03-10 | $1.93M 10-K · filed 2025-03-10 | $1.90M 10-K · filed 2024-02-15 |
| 2023-09-30 | $482.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $946.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.45M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $464.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $964.00K 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | $500.00K 10-Q · filed 2024-05-07 | ||||
| 2022-12-31 | $1.80M 10-K · filed 2024-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |